A recent breakthrough was the discovery of the involvement of mutations in the genes for isocitrate dehydrogenase 1 (IDH1) and, less frequently, IDH2[13-15] in grade II/III gliomas and secondary glioblastomas. This evidence concerns the gene IDH1 and central nervous system cancer.